Cubist Systematic Strategies, LLC Summit Therapeutics Inc. Transaction History
Cubist Systematic Strategies, LLC
- $20.3 Billion
- Q2 2025
A detailed history of Cubist Systematic Strategies, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 18,800 shares of SMMT stock, worth $339,716. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,800Holding current value
$339,716% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding SMMT
# of Institutions
269Shares Held
92.7MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$609 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$206 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$143 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$72.6 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$70.6 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.64B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...